Emerging Biomarkers for Predicting Acute Kidney Injury in Critically Ill Patients

Page 28

Journal of MedVerse Research & Practice

nurexus.com

Emerging Biomarkers for Predicting Acute Kidney Injury in Critically

Ill Patients

Dr. Sharif,

Dr. Kumari,

Dr. Nakshatra,

Postgraduate, Associate Professor, Professor

Department of Medicine, Karpaga Vinayaga Medical College & Hospital,

Chennai.

Email ID: sharifdr@gmail.com

Submission Date: 22.11.2023

Accepted Date: 18.12.2023

Published Date: 31.12.2023

article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits

unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Abstract

Acute kidney injury (AKI) is a widespread and frequently severe condition, particularly among patients in critical

care settings. Timely identification and precise prognostication of AKI are crucial for enhancing patient care

outcomes and reducing medical expenses. Traditional methods for diagnosing AKI, such as evaluating serum

creatinine and urine output, often lack sufficient sensitivity and specificity, leading to delays in treatment and

suboptimal patient outcomes (27, 28). This review article will examine the latest findings regarding novel

biomarkers and their potential for predicting AKI progression in critically ill individuals.

In recent years, advancements in molecular and biochemical studies have unveiled several new biomarkers that

demonstrate improved sensitivity or specificity when compared to traditional biomarker methods. Several

biomarkers, including Kidney Injury Molecule-1 (KIM-1), Neutrophil gelatinase-associated lipocalin (NGAL),

and Cystatin C, have shown potential in identifying patients at risk for acute kidney injury (AKI). This

identification enables healthcare professionals to implement appropriate interventions and develop targeted

treatment plans for patients exhibiting these biomarkers.

This assessment offers a thorough examination of current biomarker research for predicting AKI. It explores

recent developments, present limitations, and potential clinical uses in the future. The primary objective is to

highlight potential kidney biomarkers and their possible benefits in quickly detecting AKI among severely ill

patients.

Keywords: Acute Kidney Injury (AKI), Biomarkers, KIM-1, NGAL, Cystatin C

Introduction

Acute kidney injury (AKI), formerly known as acute renal failure, is a significant medical condition

characterized by a sudden decline in kidney function, which is often reversible. This syndrome primarily

affects critically ill individuals, especially those receiving care in the intensive care unit (ICU). Acute

kidney injury (AKI) significantly increases patient morbidity, mortality, and healthcare costs. Prompt

and accurate detection of AKI is crucial for minimizing these adverse outcomes.

Traditionally, the diagnosis of acute kidney injury (AKI) has relied on meeting both urine output and

serum creatinine criteria. Creatinine, a byproduct of muscle metabolism eliminated through the kidneys,

serves as an indicator of glomerular function. However, it often exhibits changes with a considerable

time lag. Extra-renal mechanisms compensate for chronic kidney damage, causing a delay in serum

Page 29

creatinine elevation. This delay, however, limits the effectiveness of serum creatinine as an early

indicator of acute kidney injury (AKI), as kidney damage may occur before a corresponding rise in

serum creatinine is observed. Furthermore, creatinine levels can be influenced by various individual

factors such as age, muscle mass, and hydration status, potentially leading to inaccurate AKI diagnoses.

Evaluating acute kidney injury (AKI) through urine output measurement has limitations as a diagnostic

method. This approach requires meticulous urine collection and may not detect early stages of kidney

damage effectively. Additionally, the administration of diuretics in critical care environments can

further obscure an accurate assessment of urine production, making this measurement less reliable as an

indicator of kidney function.

Given the limitations of conventional biomarkers, scientists are now focusing on discovering new

biomarkers that offer enhanced sensitivity and specificity for the early identification of AKI. These

molecular and biochemical characteristics are recognized for their highly beneficial functions. They can

identify minor alterations in kidney function before they become apparent through conventional

indicators like creatinine levels. This early detection allows for prompt intervention, significantly

minimizing the extent of kidney damage. These biomarkers offer greater accuracy than previous

measurements across a wider range of patients, as they are less influenced by variables such as age or

hydration levels. This article reviews recent advancements, discusses their clinical relevance, and

explores the obstacles and prospects in identifying biomarkers for AKI [1-5].

New biomarkers for Acute Kidney Injury prediction

In the field of critical care medicine, current research efforts are focusing on identifying new biomarkers

for the early recognition and assessment of acute kidney injury (AKI). This emerging investigative

direction aims to enhance the timely detection and diagnosis of AKI in critically ill patients. These ten

biomarkers facilitate earlier identification, enhanced precision, and improved outcomes for patients.

Currently, the most significant biomarkers under investigation include:

Kidney Injury Molecule-1 (KIM-1)

KIM-1, a type 1 transmembrane glycoprotein, is barely detectable in healthy kidneys but becomes

significantly expressed following renal damage. Numerous studies across various clinical contexts have

demonstrated its effectiveness in predicting AKI. As a unified indicator, KIM-1 serves as a biomarker

for kidney damage, offering exceptional sensitivity and specificity. This marker typically detects renal

injury earlier than conventional indicators like serum creatinine, allowing for more timely intervention.

Nevertheless, challenges remain in standardizing testing protocols and establishing clinically relevant

cutoff values.

Neutrophil Gelatinase-Associated Lipocalin (NGAL)

Damage to the kidneys also triggers the production of neutrophil gelatinase-associated lipocalin

(NGAL), a protein synthesized by neutrophils and damaged kidney tubule cells. Due to its rapid

increase following kidney injury, NGAL is considered a valuable biomarker for the early identification

of acute kidney injury (AKI). [16]. NGAL has demonstrated significant efficacy as an AKI indicator

across various clinical contexts, including post-cardiac surgery and sepsis cases. Nevertheless, its

reliability has occasionally been questioned due to elevated NGAL levels observed in non-renal

conditions, such as systemic inflammation. To maximize its diagnostic effectiveness, a comprehensive

clinical evaluation is essential.

Page 30

Cystatin C

All nucleated cells produce CystatinC, a protein with a low molecular weight that easily passes through

the glomerulus. Similarly, creatinine has emerged as an important indicator of kidney function,

particularly in assessing glomerular filtration rate (GFR) and identifying acute kidney injury (AKI) in its

early stages. Cystatin C has several advantages, including the absence of age-related and muscle mass-

related effects that impact creatinine levels. It responds more quickly to changes in GFR, making it a

more reliable biomarker for identifying patients who are at high risk of AKI. But extrarenal conditions,

such as thyroid disease and corticosteroid use, can influence cystatin C levels.

Challenges

Although novel biomarkers are attractive candidates for predicting acute kidney injury (AKI), their

clinical application is marred by substantial hurdles. This is essential to fully utilize them in improving

patient care outcomes.

Challenges of Standardization and Variability essays

There is little debate that the absence of standardized testing protocols limits the widespread

implementation of new biomarkers. There is considerable heterogeneity in the testing techniques,

measurement standards, and definition of reference value ranges used, which may complicate results

interpretation and comparison across studies. To drive clinical implementation, standard laboratory

practices and recognized clinical thresholds are essential.

Costly inaccessible

One of the biggest barriers to the widespread adoption of biomarker tests is cost and availability. Such

advanced diagnostics are normally only accessible in certain healthcare facilities so they are only used

in specific patient groups. Implementing these advanced AKI prediction methods extensively would

require overcoming financial challenges, as well as functioning in practice.

Need for Rigorous Validation

While biomarkers hold great potential to improve clinical decision-making, their implementation in

practice mandates further development until their safety and effectiveness are verified over a range of

patient populations and clinical settings. They need strong evidence to prove the accuracy, consistency,

and clinical significance. Moreover, because of the investment in the, it is important to assess the added

value of the use of these biomarkers compared with classical markers such as serum creatinine in the

prediction of AKI. 10

Collective Analysis and integration challenges

One of the key challenges is how to make sense of these biomarker data in the clinic. Various

combinations of biomarkers will need to be studied for this to generate diagnostic and prognostic

information and be incorporated into existing paradigms and processes.

Overcoming such challenges is crucial for the successful implementation of novel biomarkers in clinical

practice, including the opportunity for timely AKI detection and improved patient outcomes. We will

discuss innovative technologies and partnerships, in later sections, that could aid in addressing these

barriers. To successfully incorporate these novel biomarkers into clinical practice for early AKI

detection and targeted patient treatment and outcome improvement, these challenges must be addressed.

Further sections will reflect on technological innovations or collaborative problem-solving to address

these challenges in this research domain. 11,12

Page 31

Future Research Directions

Novel biomarkers to predict acute kidney injury (AKI): An expanding field with exciting possibilities

for interesting research. In this section, we discuss potential improvements, and innovations, that may

enhance AKI prediction in critically ill patients.

Multi-Omics Methodologies

Collectively, genomics, transcriptomics, proteomics, and metabolomics have ushered in an era of

biomarker discovery. Conclusion: Integrated omics data analysis has the potential to advance a holistic

view of the molecular events in AKI. These strategies potentially provide novel biomarkers and an

enhanced performance of biologics to improve AKI prediction. [1,5,11,12].

AI is machine learning and basic learning

It doesn't matter that specific this one piece of information is Admins are almighty. These emerging

techs can mine big data, detect intricate and profuse patterns, and build predictive models. Artificial

Intelligence in the Prediction of AKI continues to be an under-appreciated and preventable condition

and additional opportunities for the disease, and underlying risk factors, to be more widely recognized

exist. [10].

Multimarket Panels to Improve AKI Prediction. This reinforces the growing effort to consider more

than one biomarker, with different targets in the pathway of injury to the kidneys to improve both

sensitivity and specificity for diagnosis. The incorporation of these markers and the best combinations

of them are still being refined. [1,7].

Personalized Medicine

With how things work in the healthcare industry, Personalized medicine is one important thing. This

approach aims to improve patient outcomes by customizing treatment recommendations based on

individual differences. This interest and shift towards an individualized strategy is mirrored in acute

kidney injury (AKI) prediction studies that are integrating not just biomarker profiles, but rather patient-

level determinants such as genetic background, comorbidity, and drug treatments. [1,5,6,8].

Point-of-Care Testing: Much research is being done to produce portable diagnostics for AKI

biomarkers. These rapid, portable diagnostic devices may help facilitate decisions in the clinic.

Implementing bedside diagnostics may greatly improve patient care and renal preservation in the setting

of AKI, regardless of the clinical setting. [1,9].

This modern research area of AKI prediction can lead to a promising new exploration. These

innovations may change the way AKI is recognized, managed, and treated in critically ill patients.

Reduction is never a solo effort, and to effectively move forward these people will need to connect with

people like those in health care, research, and technology, as well as those who understand data in the

real world, so such advancements can indeed be implemented.

A multidisciplinary approach

The creation and execution of innovative biomarkers for the prediction of acute kidney injury (AKI)

necessitate a collaborative, interdisciplinary approach. This section will examine the benefits of

integrating expertise from various domains and will explore how distinct disciplines can enhance the

precision of AKI prediction methodologies.

Page 32

Clinical Collaboration

Healthcare professionals play a crucial role as essential conduits between scientific inquiry and patient

care. Their experiential knowledge and clinical acumen are critical for identifying healthcare needs,

setting biomarker thresholds, and ensuring the practical applicability of AKI prediction models across

diverse clinical environments. The effective integration of novel biomarkers significantly hinges on

strong partnerships between healthcare providers and research scientists. [2,10].

Bioinformatics and Data Interpretation:

The management of the vast datasets generated by omics technologies and biomarker studies is

predominantly facilitated by bioinformaticians and data analysts. Their expertise in data analysis, pattern

recognition, and predictive modeling enables them to exploit the potential of emergent biomarkers in

forecasting AKI. These professionals are essential in the formulation of standardized analytical

protocols and in ensuring the reproducibility of findings. [2,13].

Scientific and Technological Innovation

The advancement of advanced diagnostic tools, such as point-of-care testing devices, is heavily

dependent on the knowledge of engineers and technologists. These experts are integral in translating

scientific advancements into practical applications that can be utilized directly in patient care settings.

Moreover, engineers play a pivotal role in enhancing the efficacy and cost-effectiveness of tests

designed to identify biomarkers. [2,12].

Regulatory Oversight

Regulatory bodies, such as the US Food and Drug Administration (FDA), bear the responsibility for the

evaluation and authorization of medical diagnostics and therapeutic interventions. Engaging closely with

these regulatory organizations is paramount to ensure that novel biomarkers meet safety and efficacy

standards prior to their widespread implementation in clinical practice. The regulatory approval pathway

is a critical phase in transitioning biomarkers from laboratory research to practical medical application.

This step is vital for converting laboratory discoveries into tangible healthcare solutions. [2,3].

Patient Advocacy and Ethical Considerations

The trajectory of research in AKI prediction is profoundly shaped by patients and their advocates. It is

imperative to uphold patient rights, perspectives, and confidentiality. Additionally, thorough

interdisciplinary dialogues must encompass ethical considerations, including informed consent

processes, data-sharing agreements, and the ethical utilization of biomarkers. [11,12].

Interdisciplinary collaboration empowers researchers to more effectively navigate the challenges

associated with predicting acute kidney injury (AKI) and accelerates the identification and

implementation of novel biomarkers. By assembling diverse teams of specialists from various fields, a

holistic strategy can be devised to address the clinical, technological, regulatory, and ethical challenges

involved, ultimately enhancing patient outcomes in critical care environments.

Summary

Acute kidney injury (AKI) is a sudden and often reversible decline in kidney function that mainly

affects critically ill patients, leading to high morbidity, mortality, and healthcare costs. Conventional

diagnostic markers such as serum creatinine and urine output are limited by delayed response and poor

sensitivity. As a result, research has shifted toward identifying novel biomarkers that can detect kidney

injury earlier and more accurately.

Page 33

Among the promising biomarkers, Kidney Injury Molecule-1 (KIM-1), Neutrophil Gelatinase-

Associated Lipocalin (NGAL), and Cystatin C have shown strong potential for early detection of AKI.

KIM-1 becomes highly expressed after renal damage, NGAL rises rapidly after injury, and Cystatin C

reflects changes in glomerular filtration rate without being affected by age or muscle mass. Despite their

promise, challenges such as high costs, lack of standardization, and limited clinical validation restrict

their widespread use.

Future research is focusing on integrating multi-omics approaches, artificial intelligence, and

multimarker panels to improve diagnostic precision. Personalized medicine, which tailors management

based on genetic and clinical profiles, is also gaining attention. Additionally, the development of point-

of-care testing devices could make AKI diagnostics more rapid and accessible, especially in critical care

settings.

A multidisciplinary approach is essential for translating these discoveries into clinical practice.

Collaboration among clinicians, researchers, bioinformaticians, engineers, regulatory authorities, and

patient advocates will help overcome technical, ethical, and implementation barriers. Such teamwork

will accelerate the integration of advanced biomarkers into healthcare, enabling earlier diagnosis, better

management, and improved outcomes for patients with acute kidney injury.

Conclusion

In summary, the emergence of innovative biomarkers for the early identification of acute kidney injury

(AKI) in critically ill patients represents a significant breakthrough in the domain of critical care

medicine. A variety of biomarkers, including KIM-1, NGAL, and cystatin C, exhibit the capacity for

expedited detection and greater precision compared to traditional diagnostic approaches. However, the

implementation of these biomarkers faces challenges concerning standardization, cost-effectiveness, and

clinical validation. Despite these challenges, the adoption of these advanced biomarkers signifies a

hopeful advancement toward enhancing patient management within intensive care settings.

Progress in multi-omics methodologies, artificial intelligence technologies, and tailored medicine

reveals substantial promise for enhancing AKI prediction capabilities. To propel the field forward and

ensure that emerging biomarkers substantially influence patient outcomes, it is essential to embrace a

collaborative framework. This strategy should involve a diverse array of stakeholders, including

healthcare professionals, researchers, engineers, data analysts, regulatory bodies, and patient advocates.

As advancements in AKI prediction continue, interdisciplinary collaboration will be crucial to optimize

the advantages of forthcoming biomarkers, ultimately fostering improved patient care in critical

healthcare environments.

Reference

Han WK, Waikar SS, Johnson A, et al. Urinary biomarkers in the early diagnosis of acute kidney injury.

Kidney Int. 2008;73(7):863-869.

Ichimura T, Bonventre JV, Bailly V, et al. Kidney Injury Molecule-1 (KIM-1), a putative epithelial cell

adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J

Biol Chem. 1998;273(7):4135- 4142.

Parikh CR, Devarajan P, Zappitelli M, et al. Postoperative biomarkers predict acute kidney injury and

poor outcomes after pediatric cardiac surgery. J Am Soc Nephrol. 2011;22(9):1737-1747.

Page 34

Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for

acute renal injury after cardiac surgery. Lancet. 2005;365(9466):1231-1238.

Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A. Accuracy of neutrophil gelatinase-

associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and

meta-analysis. Am J Kidney Dis. 2009;54(6):1012-1024.

Singer E, Elger A, Elitok S, et al. Urinary neutrophil gelatinase-associated lipocalin distinguishes pre-

renal from intrinsic renal failure and predicts outcomes. Kidney Int. 2011;80(4):405-414.

Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of

kidney function: a meta-analysis. Am J Kidney Dis. 2002;40(2):221-226.

Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate? Clin

Chem. 2002;48(5):699-707.

Murty MS, Sharma UK, Pandey VB, Kankare SB. Serum cystatin C as a marker of renal function in

detection of early acute kidney injury. Indian J Nephrol. 2013;23(3):180-183. doi:10.4103/0971-

10.

4065.111840

11.

Bayless RL, Moore AR, Hassel DM, Byer BJ, Landolt GA, Nout-Lomas YS. Equine urinary N- acetyl-β-

D-glucosaminidase assay validation and correlation with other markers of kidney injury. J Vet Diagn

Invest. 2019;31(5):688-695. doi:10.1177/1040638719867124

12.

Tsuji S. et al. Sex differences in the excretion levels of traditional and novel urinary biomarkers of

nephrotoxicity in rats. J Toxicol Sci 2017;42:615– 627.

13.

Zhang X. et al. Combined detection of urinary micro albumin, α1-microglobulin and N-acetyl-β- D-

glucosaminidase in the early diagnosis of diabetic nephropathy. Pak J Med Sci 2017;33:1324–1327.